

Date: March 7, 2025

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,

Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) **Mumbai-400 051**

USFDA Inspection at Unit-1 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited

This is to inform you that United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-1 of Shilpa Pharma Lifesciences Limited, located at Raichur from March 3-7, 2025. On conclusion of inspection, we received 1 (one) observation in form 483, which is procedural in nature.

The company will closely work with the agency and remain committed to address this observation comprehensively within stipulated time.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer